Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Brexucabtagene autoleucel |
Synonyms | |
Therapy Description |
Tecartus (brexucabtagene autoleucel) are autologous T-cells engineered to express an anti-CD-19 chimeric antigen receptor (CAR), which may potentially target CD-19-expressing tumor cells (PMID: 32242358). Tecartus (brexucabtagene autoleucel) is FDA approved for use in adult patients with relapsed or refractory mantle cell lymphoma and patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov). |